Thomas Fletcher Tedder (May 14, 1956-March 18, 2024) was an American immunologist. He is best known for his work in the fields of B lymphocyte biology and regulation. He was the Alter E. Geller Professor for Research in Immunology at Duke University[1]
Career
editTedder received his Ph.D. in molecular cell biology from the University of Alabama in 1984 and completed his postdoctoral training as a research fellow in pathology at Harvard Medical School. He was a faculty member at Dana–Farber Cancer Institute and Harvard Medical School from 1985 to 1998 before joining Duke University in 1993 as its founding chairman of immunology.[2] Tedder studies the structure and function of B lymphocyte cell surface molecules that regulate B cell function, activation, and signal transduction. He currently has 401 total publications and 25 issued patents relating to B cells and their products, including CD19, CD20, CD22, CD83, and L-selectin.[3] He has founded four biotherapeutic companies, including Angelica Therapeutics, Cellective Therapeutics, Cellective BioTherapy[4] and most recently, Antigenomycs, Inc.
The drug Tedder developed at Cellective Therapeutics, inebilizumab,[5] has now been approved for NMSOD use in the United States[6] under the clinical name Uplizna.
References
edit- ^ "Duke Immunology". immunology.duke.edu. Archived from the original on 2016-08-03. Retrieved 11 August 2018.
- ^ "Featured LRF Researcher: Thomas F. Tedder, PhD - Lymphoma Research Foundation - Welcome". Archived from the original on 2015-09-12. Retrieved 2015-10-19.
- ^ "Angelica Therapeutics: Best in Class Fusion Toxins". angelicatherapeutics.com. Retrieved 11 August 2018.
- ^ "Article". www.bizjournals.com. 2015.
- ^ "Accelerating Immunotherapy | Duke Department of Neurosurgery". neurosurgery.duke.edu. Retrieved 2020-07-08.
- ^ "Uplizna launch is a 'testament' to NC's prowess in drug R&D | WRAL TechWire". 2020-07-01. Retrieved 2020-07-08.